hVIVO plc (FRA:CRO)

Market Cap	47.14M -67.3%
Revenue (ttm)	63.54M -19.0%
Net Income	6.16M -69.7%
EPS	0.01 -69.5%
Shares Out	n/a
PE Ratio	7.65
Forward PE	n/a
Dividend	0.00 (4.13%)
Ex-Dividend Date	May 15, 2025

Volume	n/a
Average Volume	760
Open	0.0580
Previous Close	0.0590
Day's Range	0.0580 - 0.0580
52-Week Range	0.0440 - 0.2500
Beta	n/a
RSI	49.22
Earnings Date	Apr 10, 2026

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company in the United Kingdom, Europe, and North America. The company is involved in the testing of vaccines and antivirals using human challenge clinical trials; and provision of laboratory services, including assay development, cell based assays, molecular, immunology, virology, clinical field trail logistics, and biomarker analysis services. It has a portfolio of human challenge study models for conditions, such as RSV, influenza, COVID-19, hMPV, HRV, asthma, malaria, and C...

• Industry: Commercial Physical and Biological Research
• CEO: Yamin Khan
• Employees: 301
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: CRO

Financial Performance

In 2024, hVIVO's revenue was 66.22 million, an increase of 12.87% compared to the previous year's 58.67 million. Earnings were 10.65 million, a decrease of -33.90%.

Financial numbers in GBP